Defining a prognostic molecular profile for ductal adenocarcinoma of the pancreas highlights known key signaling pathways. Issue 10 (October 2012)

• Record Type: Journal Article
• Authors: Frampton, Adam E; Krell, Jonathan; Giovannetti, Elisa; Krell, Daniel; Stebbing, Justin; Castellano, Leandro; Jiao, Long R
• Is Part Of: Expert review of anticancer therapy. Volume 12:Issue 10(2012)
• Page Start: 1275
• Page End: 1278
• Publication Date: 2012-10
• Subjects: AKT -- biomarker -- CBL -- copy number variation -- miR-519d -- miRNA -- mRNA -- pancreatic ductal adenocarcinoma -- PI3K -- prognostic -- SRC; Cancer -- Treatment -- Periodicals; 616.99406
• DOI: 10.1586/era.12.108
• Languages: English
• ISSNs: 1473-7140

Abstract

There has been very little progress in improving outcomes for patients with pancreatic ductal adenocarcinoma (PDAC) over the past few decades. High-throughput array profiling has made it possible to discover new assays to diagnose or prognose PDAC more accurately based on the genetic profile of an individual tumor. To improve patient survival, there is a need to extract the most practical data to define tumor subgroups and personalize anticancer therapy. In the evaluated study, a multiplatform, survival-based analysis of molecular changes was performed for PDAC to discover clinically useful biomarkers. A composite score predictive for survival was calculated for individual genes, taking into account the DNA copy-number and any regulation by miRNAs. Several genes involved in the PI3K/AKT and SRC signaling pathways were identified and further investigated.